| Name | Title | Contact Details |
|---|
Sampson Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Sampson Regional Medical Center is based in Clinton, NC. You can find more information on Sampson Regional Medical Center at www.sampsonrmc.org
Onslow Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Onslow Memorial Hospital is based in Jacksonville, NC. You can find more information on Onslow Memorial Hospital at www.onslowmemorial.org
Wellteq is creating the future of precision wellness through a digital wellbeing ecosystem taking users from point of prevention through to point of care. Delivered into the corporate health and insurance sector to drive user engagement through a personalised wellness journey. wellteq uses a range of data types from wearable devices, sensors, biomarkers and user-generated data that, in combination with machine learning and artificial intelligence enables individual-level insights into Stress, Fatigue, Sleep Quality, Cognitive Function and Activity levels. Behavioural science and content targeting use biometric and behavioural analytics to deliver personalised wellness insights and practical recommendations to build engagement, agency and more effective sustainable management of personal wellness. Programs are highly customisable and provide an experience packed with gamification, group projects, social interaction rewards and charity all to maximise healthy behavioural change. With customisation comes flexibility, which is paramount for businesses of all shapes and sizes around the world today.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.